CAJ | 학술논문

目的：探讨宫颈癌3DBT中直肠实测剂量与参考剂量的相关性，评估直肠实测剂量的意义。方法选取50例行宫颈癌根治性放疗患者，在完成全盆腔外照射后行三维近距离治疗（3DBT）。依据ICRU38号报告推荐的直肠监测方法，通过在体监测得到直肠实测剂量、参考点剂量（ DICRU ）及D2．0 cm3，在计划系统中得到计划剂量。应用配对t检验比较它们的差异，采用Pearson法进行相关分析。结果直肠实测剂量大于计划剂量（3．48∶3．25，P＝0．000）、小于DICRU（3．48∶3．71， P＝0．000）和D2．0 cm3（3．48∶3．87，P＝0．002）。直肠实测剂量与计划剂量存在线性关系，二者偏差百分数为－20％～40％，偏差平均数为8．16％，其中63％宫颈癌患者偏差＜±10％，最大偏差达60％。实测剂量与DICRU相关性强（ r＝0．722）、与D2．0 cm3相关性弱（ r＝0．284）。结论宫颈癌3DBT中直肠实测剂量存在一定偏差，但与计划剂量呈线性相关。实测剂量及计划剂量均会低估直肠剂量参考点剂量。直肠在体监测方法可作为有效的质量控制手段。
목적：탐토궁경암3DBT중직장실측제량여삼고제량적상관성，평고직장실측제량적의의。방법선취50례행궁경암근치성방료환자，재완성전분강외조사후행삼유근거리치료（3DBT）。의거ICRU38호보고추천적직장감측방법，통과재체감측득도직장실측제량、삼고점제량（ DICRU ）급D2．0 cm3，재계화계통중득도계화제량。응용배대t검험비교타문적차이，채용Pearson법진행상관분석。결과직장실측제량대우계화제량（3．48∶3．25，P＝0．000）、소우DICRU（3．48∶3．71， P＝0．000）화D2．0 cm3（3．48∶3．87，P＝0．002）。직장실측제량여계화제량존재선성관계，이자편차백분수위－20％～40％，편차평균수위8．16％，기중63％궁경암환자편차＜±10％，최대편차체60％。실측제량여DICRU상관성강（ r＝0．722）、여D2．0 cm3상관성약（ r＝0．284）。결론궁경암3DBT중직장실측제량존재일정편차，단여계화제량정선성상관。실측제량급계화제량균회저고직장제량삼고점제량。직장재체감측방법가작위유효적질량공제수단。
Objective To explore the correlation between the dose measured in the rectum and reference dose in three?dimensional brachytherapy ( 3DBT ) for cervical cancer, and to evaluate the significance of the dose measured in the rectum. Methods Fifty patients receiving radiotherapy for cervical cancer were selected, and 3DBT was performed after pelvic external beam radiotherapy. According to the rectal monitoring method recommended in the report ICRU38, in vivo monitoring was applied to obtain the dose measured in the rectum, reference point dose ( DICRU ) , and D2 cm3 , and the planned dose was obtained from the planning system. The differences in these values were determined by the paired t?test and correlation analysis was performed with Pearson test. Results The dose measured in the rectum was higher than the planned dose (3. 48 vs. 3. 25,P=0. 000), and lower than DICRU(3. 48 vs. 3. 71,P=0. 000) and D2 cm3(3. 48 vs. 3. 87,P=0. 002). A linear relationship existed between the dose measured in the rectum and the planned dose, with a deviation percentage of-20% to 40% and an average deviation of 8. 16%;63%of the patients with cervical cancer had a deviation of<± 10%;the maximum deviation was 60%. The dose measured in the rectum had a strong correlation with DICRU(r=0. 722), but a weak correlation with D2 cm3 ( r=0. 284) . Conclusions During 3DBT for cervical cancer, the dose measured in the rectum has certain deviations, but has a linear correlation with the planned dose. Both the dose measured and the planned dose underestimate the dose at the reference point in the rectum, and in vivo rectal monitoring may be an effective method for quality control.